Revolution Medicines has partnered Royalty Pharma for $2bn in flexible funding to support the independent worldwide ...

Royalty Pharma will pay up to $2 billion to Revolution Medicines to support the development and sales of an experimental drug ...

Passive investing in index funds can generate returns that roughly match the overall market. But you can significantly boost your returns by picking above-average stocks. For example, the Royalty ...

Royalty Pharma’s first quarter reflected a stable performance, with revenue in line with Wall Street expectations and ...

Revolution Medicines projected its cash and equivalents of $2.1 billion would last into the second half of 2027. With new ...

Revolution Medicines, a Californian oncology specialist developing targeted therapies for RAS-addicted cancers, has partnered with Royalty Pharma on $2 billion in flexible funding to support the ...

A total of $1.25 billion of the money pledged by Royalty has been agreed in exchange for tiered royalties on net sales of ...

Royalty Pharma will provide up to $1.25 billion in exchange for a synthetic royalty on annual worldwide net sales of daraxonrasib (and zoldonrasib if approved in an overlapping daraxonrasib ...

--Royalty Pharma plc today announced a $2 billion funding arrangement with Revolution Medicines, consisting of a synthetic royalty of up to $1.25 billion on daraxonrasib and a senior secured loan ...

Merck announced ACIP voted to recommend Enflosnia (clesrovimab-cfor) as a treatment option for RSV in infants younger than 8 months of age who are born during or entering their first RSV season.

Royalty Pharma Plc stock reached a new 52-week high, hitting $35.41, marking a significant milestone for the company. This achievement reflects a 29.84% increase over the past year, with an ...

According to Benzinga Pro, Royalty Pharma's peer group average for short interest as a percentage of float is 3.78%, which means the company has more short interest than most of its peers. Did you ...